To the full analysis
Buyback calculator for CRISPR Therapeutics
CRISPR Therapeutics stock: key metrics
CRSPCRISPR Therapeutics had an operating margin of −16,191.4% and a return on invested capital (ROIC) of −20.9% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2014 | no data | no data | no data |
| 2015 | −4,990.3% | −10,416.6% | −10,456.7% |
| 2016 | −717.9% | −1,319.3% | −449.3% |
| 2017 | −70.3% | −157.7% | −166.7% |
| 2018 | −3,541.9% | −5,087.8% | −5,281.1% |
| 2019 | 38.1% | 16.1% | 23.1% |
| 2020 | −37,369.7% | −49,295.5% | −48,520.9% |
| 2021 | 88.9% | 40.9% | 41.4% |
| 2022 | −25,186.7% | −154,394.7% | −149,122.7% |
| 2023 | 64.8% | −60.1% | −41.5% |
| 2024 | −215.0% | −1,333.0% | −1,046.4% |
| 2025 | −6,537.0% | −16,191.4% | −16,569.8% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2014 | 95.5% | no data | −100.0% |
| 2015 | 88.8% | −27.3% | −16.2% |
| 2016 | −10.0% | −22.8% | −6.7% |
| 2017 | −36.4% | −17.6% | −25.2% |
| 2018 | −42.1% | −35.0% | −33.7% |
| 2019 | 7.1% | 6.3% | 6.3% |
| 2020 | −21.0% | −20.3% | −19.1% |
| 2021 | 15.7% | 16.9% | 13.7% |
| 2022 | −34.7% | −22.2% | −29.0% |
| 2023 | −8.2% | −48.0% | −6.9% |
| 2024 | −19.0% | −17.1% | −16.3% |
| 2025 | −30.3% | −20.9% | −25.7% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Aug 2022)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.